Sarepta Therapeutics, Inc. (SRPT): debt financing — Sarepta exchanges $700M convertible notes for $602M new 4.875% notes due 2030 plus stock and cash

Sarepta Therapeutics, Inc.

Exchanged $700M of 1.25% Convertible Notes due 2027 for $602M of 4.875% Convertible Notes due 2030, 5.85M common shares, and ~$123.3M cash.
New notes mature Sept 1, 2030; initial conversion price ~$60.00/share (191.5% premium over $20.58 close on Aug 20, 2025).
Concurrent private placement of 1,106,806 shares to J. Wood Capital at $18.07 per share.
New notes bear 4.875% cash interest, payable semiannually; callable from Sept 6, 2028 if stock price ≥ 130% of conversion price.
Holders may convert upon stock price triggers (≥130% of conversion price for 20 of 30 days) or specified corporate events.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Sarepta Therapeutics, Inc. incurred convertible notes of $602.0 million in aggregate principal amount with U.S. Bank Trust Company, National Association at 4.875% maturing September 1, 2030.

Instrument: convertible notes
Principal: $602.0 million in aggregate principal amount
Counterparty: U.S. Bank Trust Company, National Association
Rate: 4.875%
Maturity: September 1, 2030
Event: incurrence

Exact text from the filing

party thereto agreed to exchange with the Company $700.0 million in aggregate principal amount of Existing Convertible Notes held by them for consideration consisting of (i) $602.0 million in aggregate principal amount of 4.875% Convertible Senior Notes due 2030 (the “New Convertible Notes”), (ii) an aggregate of 5,851,693 shares of the Company’s common stock, par

View on SEC.gov

Browse all debt financings →

Sarepta Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-192794

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.